X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.astrazeneca-us.com/media/press-releases/2024/fasenra-approved-for-treatment-of-children-aged-6-to-11-with-severe-asthma.html
https://www.fiercepharma.com/marketing/astrazeneca-steps-show-fasenra-helping-patients-step-out-ad-push-asthma-drug
https://www.fiercepharma.com/marketing/one-look-astrazeneca-unifies-patient-physician-messaging-asthma-blockbuster-fasenra
https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-messina-phase-iii-trial.html
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-rejects-astrazeneca-treatment-chronic-nasal-condition-2022-03-14/
https://endpts.com/gsk-looks-to-stand-out-in-the-severe-asthma-space-with-at-home-injections-for-kids-6-to-11-years-old/
https://www.pharmatimes.com/news/az_announces_us_fast_track_designation_for_il-5_inhibitor_fasenra_1383156
http://www.pharmafile.com/news/576625/astrazeneca-drug-evaluated-nine-eosinophilic-diseases
https://www.indiainfoline.com/article/news-top-story/astrazeneca-pharma-launches-benralizumab-fasenra-for-asthma-patients-stock-skyrockets-11-121042200018_1.html
https://www.astrazeneca.com/media-centre/press-releases/2020/fasenra-eliminated-oral-corticosteroid-use-in-a-majority-of-ocs-dependent-patients-with-asthma-in-ponente-phase-iiib-trial.html
https://endpts.com/fasenra-shows-positive-phiii-topline-data-for-nasal-polyps-tightening-race-with-gsks-nucala/
https://www.astrazeneca.com/media-centre/press-releases/2020/new-analyses-from-breztri-aerosphere-phase-iii-ethos-trial-to-be-presented-at-the-european-respiratory-society-international-congress-2020.html
http://www.pharmatimes.com/news/azs_fasenra_study_confirms_robust_efficacy_in_eosinophilic_asthma_1346400
https://www.federalregister.gov/documents/2020/03/04/2020-04363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fasenra
https://www.biospace.com/article/fda-approves-astrazeneca-s-fasenra-for-asthma/?s=95
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761070
https://www.reuters.com/article/us-astrazeneca-fasenra/astrazeneca-respiratory-business-gets-boost-from-3-drug-inhaler-results-idUSKCN1VI0KB
http://www.pharmatimes.com/news/az_bags_two_extensions_in_latest_chmp_decisions_1292946
https://www.fiercepharma.com/pharma/astrazeneca-s-copd-triplet-breztri-rival-to-gsk-s-trelegy-nabs-first-nod-from-japan
https://www.fiercepharma.com/pharma/glaxosmithkline-s-nucala-scores-convenience-boost-at-home-dosing-options
https://www.fiercepharma.com/marketing/sanofi-and-regeneron-delves-deep-uncontrolled-asthma-digital-awareness-campaign
https://www.fiercepharma.com/pharma/novartis-xolair-looking-to-hold-blockbuster-status-positive-sinusitis-data
https://www.fiercepharma.com/pharma/az-s-fasenra-offers-severe-asthma-patients-two-years-benefits-analysis
https://www.fiercepharma.com/pharma/fasenra-s-strong-showing-hes-trial-puts-pressure-gsk-s-nucala
http://www.pharmatimes.com/news/fasenra_granted_orphan_drug_designation_by_fda_1277495
https://www.fiercepharma.com/pharma/as-advair-generic-hits-gsk-looks-to-oncology-as-new-growth-point-alongside-shingrix-and-hiv
https://www.bloomberg.com/news/articles/2019-01-13/astrazeneca-departures-continue-as-medical-chief-bohen-exits
http://www.pharmatimes.com/news/nice_recommends_fasenra_injection_as_asthma_alternative_1273752
http://www.pharmatimes.com/news/us_grants_az_fasenra_orphan_drug_status_for_rare_autoimmune_disease_1265163
https://scrip.pharmaintelligence.informa.com/SC124179/ICER-On-Asthma-Biologics-5079-Price-Discounts-Needed-To-Meet-Value-Assessment-Metrics
https://www.fiercepharma.com/marketing/gsk-execs-change-their-tune-as-az-sanofi-heap-pressure-nucala
https://www.fiercepharma.com/marketing/roche-novartis-grab-fda-ok-for-new-version-aging-blockbuster-xolair
https://www.biopharmadive.com/news/icer-finds-5-asthma-biologics-overpriced-including-sanofis-dupixent/533308/
http://www.pharmatimes.com/news/az_fasenra_shows_long-term_efficacy_in_eosinophilic_asthma_1252684
https://www.fiercepharma.com/marketing/astrazeneca-teams-geisinger-to-offer-integrated-ehr-asthma-applications-for-doctors-and
https://www.fiercepharma.com/pharma/nice-says-yes-to-astrazeneca-s-fasenra-but-only-when-its-gsk-rival-can-t-be-used
http://www.pharmatimes.com/news/nice_backs_az_asthma_biologic_fasenra_1244396
Market Place
Share 
